Immunologic aspects of sublingual immunotherapy in the treatment of allergy and asthma.
Recently interest has been focused on the administration of allergen specific immunotherapy by the oral route particularly sublingually. The mechanism by which sublingual immunotherapy exerts its effects remain unclear. Most likely, allergen captured within the oral mucosa by Langerhan's-like dendritic cells play a role in subsequent T cell responses. There is a growing body of evidence to support the role of regulatory T cells in controlling the development of allergic diseases. Nevertheless, there remains a lack of firm evidence that sublingual immunotherapy induces regulatory T cells. New vaccine developments with the increasing understanding of the molecular engineering techniques are on the way to offer the opportunity to design recombinant allergens that are safe, effective and easy to administer. In addition, the idea of using adjuvants along with allergen within the oral cavity is another promising approach.
Bahceciler
Nerin Nadir
NN
Division of Pediatric Allergy and Immunology, School of Medicine, Marmara University, Istanbul, Turkey. nerin74@attglobal.net
Ozdemir
Cevdet
C
Barlan
Isil Berat
IB
D000276:Adjuvants, Immunologic; D000286:Administration, Sublingual; D000485:Allergens / Q000276:immunology; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy*; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D007167:Immunotherapy / Q000379:methods*; D009061:Mouth Mucosa / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014612:Vaccines / Q000276:immunology
D000276:Adjuvants, Immunologic; D000485:Allergens; D018926:Anti-Allergic Agents; D011994:Recombinant Proteins; D014612:Vaccines